All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During SOHO 2019 in Houston, US, Dr Boro Dropulic from Lentigen Technology Inc., A Miltenyi Biotec Company, Maryland, US, spoke to the Lymphoma Hub about benefits of "point-of-care" CAR T-cell therapy for the patients. He discusses how manufacturing CAR T cells at a hospital and performing local QC checks allows them to lower the cost of the therapy, reduces logistical problems, and gives more flexibility of dosing to physicians.
How could patients benefit from "point-of-care" CAR T-cell therapy?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Will CAR T-cell therapy be used in patients with other than DLBCL types of NHL?
Dr. Maloney from Fred Hutchinson Cancer Research Center, Seattle, US, shares his opinion on whether CAR T-cell therapy will be used in patients with non-Hodgkin lymphoma...
ASH 2018 | Late CAR-T effects in R/R NHL and CLL patients
The investigator presented data on the long-term safety of CD19 CAR-T infusion in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) patients
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox